Stock RLYB RALLYBIO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Company Rallybio Corporation

Equities

RLYB

US75120L1008

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
1.83 USD 0.00% Intraday chart for Rallybio Corporation +7.65% -23.43%
04-17 Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting CI
04-12 Top Premarket Decliners MT

Business Summary

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Number of employees: 43

Managers

Managers TitleAgeSince
Martin MacKay FOU
 Founder 68 31/12/17
Stephen Uden FOU
 Founder 66 31/12/17
Jonathan Lieber DFI
 Director of Finance/CFO 54 31/01/23
Zhiliang Cheng CTO
 Chief Tech/Sci/R&D Officer - -
Michael Bombara CTO
 Chief Tech/Sci/R&D Officer - -
Steven Ryder CTO
 Chief Tech/Sci/R&D Officer 73 31/12/18
Ami Bavishi IRC
 Investor Relations Contact - 17/01/22
Kim Stepanski HRO
 Human Resources Officer - -
Lauren Kriss AUD
 Comptroller/Controller/Auditor - -
Dominic Carrano AUD
 Comptroller/Controller/Auditor - -

Members of the board

Members of the board TitleAgeSince
Ron Hunt BRD
 Director/Board Member 59 28/02/19
Stephen Uden FOU
 Founder 66 31/12/17
Martin MacKay FOU
 Founder 68 31/12/17
Robert Hopfner BRD
 Director/Board Member 51 29/02/20
Christine Nash BRD
 Director/Board Member 51 03/04/22
Kush Parmar BRD
 Director/Board Member 42 31/03/18
Helen Boudreau BRD
 Director/Board Member 58 31/08/20
Paula Soteropoulos BRD
 Director/Board Member 56 30/09/20
Liu Hui BRD
 Director/Board Member 51 03/04/22
Wendy Chung BRD
 Director/Board Member 55 31/07/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,811,970 33,078,292 ( 87.48 %) 0 87.48 %

Shareholders

NameEquities%Valuation
Viking Global Investors LP
11.09 %
4,194,777 11.09 % 8 M $
5AM Venture Management LLC
9.602 %
3,630,724 9.602 % 7 M $
New Leaf Venture Partners LLC
8.732 %
3,301,603 8.732 % 6 M $
TPG Group Holdings (SBS) Advisors, Inc.
8.009 %
3,028,414 8.009 % 6 M $
Canaan Management, Inc.
5.447 %
2,059,712 5.447 % 4 M $
Novo Holdings A/S (Investment Company)
4.675 %
1,767,861 4.675 % 3 M $
abrdn, Inc.
4.568 %
1,727,067 4.568 % 3 M $
Impresa Management LLC
4.481 %
1,694,388 4.481 % 3 M $
BlackRock Advisors LLC
4.408 %
1,666,603 4.408 % 3 M $
Vanguard Fiduciary Trust Co.
2.814 %
1,063,970 2.814 % 2 M $

Company contact information

Rallybio Corp.

234 Church Street Suite 1020

06510, New Haven

+

http://www.rallybio.com
address Rallybio Corporation(RLYB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.83 USD
Average target price
13 USD
Spread / Average Target
+610.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
RALLYBIO CORPORATION Stock Rallybio Corporation
-23.43% 75.85M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RLYB Stock
  4. Company Rallybio Corporation